Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004
Business Overview: The company operates in a single segment focused on the development, acquisition, manufacture, and sale of products to improve the health and productivity of cows for the dairy and beef industry. Key products include First Defense® and Wipe Out® Dairy Wipes. The company is currently developing Mast Out®, a new product utilizing Nisin as an alternative to antibiotics for treating mastitis.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Total Revenues | $1,241,550 | $1,127,292 |
| Net Income | $172,141 | $701,490 |
| Net Income Per Share (Diluted) | $0.06 | $0.25 |
| Operating Cash Flow | $140,697 | $1,279,795 |
| Cash and Cash Equivalents | $1,994,318 | $3,877,866 (End of Q1 2003) |
| Short-term Investments | $2,266,215 | $888,320 (Dec 31, 2003) |
| Total Assets | $8,242,524 | $8,186,632 (Dec 31, 2003) |
| Shareholders' Equity | $7,578,558 | $7,370,452 (Dec 31, 2003) |
| Debt | $0 (No outstanding bank debt) | $0 |
| Gross Margin (Product Sales) | 62% | 58% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10% to $1.24 million, driven by a 20% increase in product sales to $1.22 million. Sales of First Defense® rose 28%, while Wipe Out® Dairy Wipes increased 4%.
- Profitability Decline: Net income decreased significantly to $172,141 from $701,490 in Q1 2003. The prior year included a one-time $1.1 million gain from the sale of a 50% interest in a joint venture (AgriCell Company, LLC), which is not present in the current period.
- Expense Management: Research and development (R&D) expenses decreased 30% to $221,924. Product selling expenses decreased 26% to $124,062. However, the absence of $81,000 in grant income (present in Q1 2003) impacted the bottom line.
- Liquidity Shift: While cash and cash equivalents decreased by approximately $1.36 million during the quarter, the company increased short-term investments by $1.38 million. Total liquid assets (cash + short-term investments) remained relatively stable at approximately $4.26 million.
Outlook, Risks, and Management Commentary
- Product Development (Mast Out®): The company achieved positive results in an experimental field trial for Mast Out® in January 2004. A pivotal efficacy trial is planned for 2004. Management anticipates higher R&D expenditures later in the year to fund this trial, which may result in net losses for 2004 and 2005.
- Capital Allocation: The company is investing approximately $400,000 in facility modifications to produce Nisin in-house, aiming to reduce costs and improve quality control. As of March 31, 2004, $358,000 had been invested.
- Regulatory and Market Risks:
- Regulatory Approval: Future growth depends on FDA approval for Mast Out® and USDA requalification for First Defense®.
- Customer Base: The company is heavily dependent on the dairy industry, which faces economic pressures and potential disease outbreaks (e.g., BSE, Foot and Mouth Disease).
- Supply Chain: Risks exist regarding the acquisition of essential raw materials, though the company maintains multiple vendors.
- Liquidity Position: Management believes current capital resources are sufficient to meet working capital requirements and finance operations for at least the next twelve months.
Investor Verification Checklist
- One-Time Gains: Verify the impact of the $1.1 million joint venture sale in Q1 2003 on year-over-year profitability comparisons.
- R&D Trajectory: Monitor upcoming R&D spending related to the pivotal Mast Out® trial, as management expects this to potentially cause net losses in 2004-2005.
- Customer Concentration: Note that two companies under common ownership accounted for 17% of product sales in Q1 2004.
- Grant Obligations: Review the $400,000 deferred revenue from the Maine Technology Institute, which carries a contingent payback obligation upon commercialization of Mast Out®.
- Stock Repurchase Plan: Confirm the status of the 100,000 share repurchase plan; no shares were repurchased in Q1 2004 due to share price levels.